Diarylpyrimidine compounds of Formula I are provided, wherein.
##STR1##
or a pharmaceutically acceptable salt thereof, wherein:
- Ar1 and Ar2 are independently chosen from:
- phenyl which is mono-, di-, or tri-substituted,
- 1-naphthyl and 2-naphthyl, each of which is optionally mono-, di-,
or tri-substituted, and
- optionally mono-, di-, or tri-substituted heteroaryl, said heteroaryl
having from 1 to 3 rings, 5 to 7 ring members in each ring and, in at least one
of said rings, from 1 to about 3 heteroatoms selected from the group consisting
of N, O, and S;
- R is oxygen or absent;
- Z2 is CR2; Z3 is nitrogen;
- R1 and R2 are independently chosen from hydrogen,
halogen, amino, cyano, nitro, optionally substituted alkyl, optionally substituted
alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally
substituted mono- or di-alkylamino, optionally substituted cycloalkyl, optionally
substituted (cycloalkyl)alkyl, optionally substituted (cycloalkyl)oxy, optionally
substituted (cycloalkyl)alkoxy, optionally substituted alkylthio, optionally substituted
alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted
mono- or dialkylcarboxamide; with the proviso that not all of R1, R3,
and R4 are hydrogen.
These compounds are useful in the treatment of a number of CNS and periphereal
disorders, particularly stress, anxiety, depression, cardiovascular disorders,
and eating disorders. Methods of treatments of such disorders and well as packaged
pharmaceutical compositions are also provided.
Compounds of Formula I are also useful as probes for the localization of
CRF receptors and as standards in assays for CRF receptor binding. Methods of using
the compounds in receptor localization studies are given.
|
|
|
